Dr Reddy's Q1FY27 revenue falls to ₹8,071 Cr on semaglutide hit
Dr Reddy’s Laboratories reported Q1FY27 revenue of ₹8,071 crore, down 5.6% YoY and below an analyst estimate of ₹88.05 billion, citing a ₹240 crore semaglutide API-related provision and weaker North America lenalidomide sales. Adjusted EBITDA margin was 15.4% and net cash surplus ₹3,057 crore. CEO said semaglutide commercial supplies may resume by Nov 2026.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term earnings quality (reported vs adjusted margins), semaglutide supply continuity risk, and regulatory timing risk from the USFDA Form 483, all of which can influence valuation and guidance expectations.
Market read
A concrete quarterly print plus a specific operational timeline for semaglutide supplies and a regulatory inspection outcome create actionable catalysts for re-pricing the semaglutide ramp and margin trajectory.
What to watch
Gross margin fell sharply (46.5% with a 1,039 bps YoY decline) due to multiple drivers, including solvent costs tied to the Middle East conflict, which could persist beyond the semaglutide provision window.
Background
The company’s Q1FY27 results were approved July 22, 2026 and filed with exchanges; the quarter included a semaglutide API-related provision and weaker North America lenalidomide sales.
Ticker impact
Dr Reddy reported Q1FY27 revenue of ₹8,071 crore, down 5.6% YoY, citing a ₹240 crore semaglutide API provision and weaker North America lenalidomide sales.
Near-term downside bias from the reported top-line miss and semaglutide API cost overhang, partially offset by the plan to resume commercial semaglutide supplies by November 2026.
The article provides concrete quarterly financial datapoints (revenue, margins, PAT, EPS) and a specific operational timeline (resume semaglutide supplies by Nov 2026) that can drive revisions to earnings quality and semaglutide ramp expectations.
Market effects
Signals ongoing execution and cost pressures in GLP-1/peptide API supply chains for Indian pharma, with margin sensitivity to provisions and solvent/freight costs.
Emerging Markets and India growth (31% and 17% YoY) suggests diversification is working, potentially cushioning investor sentiment toward Indian pharma ex-US.
USFDA Form 483 at a biologics facility adds regulatory overhang risk for future approvals, even as management targets abatacept approval by Dec 2026.
Counterpoint
The revenue miss may be largely provision-driven, with adjusted EBITDA margin (15.4%) and net cash surplus (₹3,057 crore) indicating the core business is not deteriorating as much as headline numbers suggest.
Key entities
- companyDr Reddy's Laboratories
Reported Q1FY27 revenue decline, semaglutide API provision, and outlined a plan to resume semaglutide commercial supplies by November 2026.
- regulatorUSFDA
Issued a Form 483 with seven observations after a Pre-Approval Inspection at the Bachupally biologics facility.
